Recent posts
As the one-year anniversary of Bristol-Myers Squibb Company’s $74bn acquisition of Celgene Corporation approaches, Scrip spoke with chief medical officer Samit Hirawat about the big pharma’s achievements during a challenging period... Read more »
It would be hard to find a more challenging time for Michelle McMurry-Heath to join the Biotechnology Innovation Organization as its CEO given the COVID-19 pandemic and the protests over racial... Read more »
[Corrected 6/17/20, 1:48 pm PT. See below.] GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the company won... Read more »
Chimeric antigen receptor T-cell therapies have shown remarkable efficacy in leukemia and lymphoma patients who relapsed or were refractory to several prior treatments, but many challenges remain in the cancer cell... Read more »
BridgeBio Pharma Inc. is poised to achieve its goal of rapidly bringing treatments for genetic diseases and genetically defined cancers to the market with two different products expected to be submitted... Read more »
Scrip talked to George Scangos about his dual roles in the pandemic response, helming Vir as the company tests antibody and siRNA approaches while working with BIO to facilitate coronavirus collaborations.... Read more »
